Back to Journals » Vascular Health and Risk Management » Volume 8

Diabetes prevalence and metabolic risk profile in an unselected population visiting pharmacies in Switzerland

Authors Rey A, Thoenes M, Fimmers R, Meier CA, Bramlage P

Received 12 July 2012

Accepted for publication 28 August 2012

Published 21 September 2012 Volume 2012:8 Pages 541—547

DOI https://doi.org/10.2147/VHRM.S35896

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Alexandre Rey,1 Martin Thoenes,1,2 Rolf Fimmers,3 Christoph A Meier,4 Peter Bramlage5

1Sanofi Aventis, Medical Department, Meyrin, Switzerland; 2Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Germany; 3Institut für Medizinische Biometrie, Informatik und Epidemiologie, Universität Bonn, Germany; 4Klinik für Innere Medizin, Stadtspital Triemli, Zürich, Switzerland; 5Institut für Pharmakologie und präventive Medizin, Mahlow, Germany

Background: Diabetes represents one of the major health challenges in Switzerland, and early diagnosis and treatment is mandatory to prevent or delay diabetes-related morbidity and mortality. For the purpose of identifying affected individuals, early screening in pharmacies is a valuable option. In this survey, we aimed to determine blood glucose and metabolic control in an unselected population of individuals visiting Swiss pharmacies.
Methods: The subjects responded to a short questionnaire and underwent a single capillary blood glucose test for screening purposes. They were classified as normal, indeterminate, impaired fasting glucose, and diabetes according to predefined blood glucose levels.
Results: A total of 3135 individuals (mean age 56 years) in 18 cantons were screened in November 2010; of these, 4.2% (95% confidence interval [CI] 3.5–4.9) had previously been diagnosed with diabetes. Diabetes was newly diagnosed in 1.9% (95% CI 1.5–2.4), and 11.5% (95% CI 10.4–12.6) had impaired fasting glucose. Subjects with impaired glucose control had an increased body mass index, a frequent family history of diabetes, hypertension, hypercholesterolemia, smoking, and a low level of physical activity. Prevalence of impaired glucose control was different between the French/Italian-speaking part of Switzerland (new diabetes 4.9%; impaired fasting glucose 12.7%) and the German-speaking part (new diabetes 1.9%; impaired fasting glucose 10.3%).
Conclusion: Our study shows a 6.1% prevalence of diabetes, of which about a third (1.9%) was previously undiagnosed, and 11.5% had impaired fasting glucose. Therefore, screening initiatives in pharmacies may be suitable for detecting people with undiagnosed diabetes.

Keywords: diabetes, pharmacy, epidemiology, screening

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice

Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE

Vascular Health and Risk Management 2015, 11:1-8

Published Date: 17 December 2014

Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T

Vascular Health and Risk Management 2014, 10:303-309

Published Date: 13 May 2014

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

Bramlage P, Zemmrich C, Ketelhut R, Wolf WP, Fronk EM, Schmieder RE

Vascular Health and Risk Management 2013, 9:475-483

Published Date: 26 August 2013

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S

Vascular Health and Risk Management 2012, 8:363-370

Published Date: 1 June 2012

Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study

Schmieder RE, Goebel M, Bramlage P

Vascular Health and Risk Management 2012, 8:177-186

Published Date: 15 March 2012

Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice

Peter Bramlage, Wolf-Peter Wolf, Thomas Stuhr, et al

Vascular Health and Risk Management 2010, 6:803-811

Published Date: 27 August 2010

Readers of this article also read:

Monitoring cancer stem cells: insights into clinical oncology

Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL

OncoTargets and Therapy 2016, 9:731-740

Published Date: 11 February 2016

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M

OncoTargets and Therapy 2015, 8:1149-1156

Published Date: 22 May 2015

Cancer patient-centered home care: a new model for health care in oncology

Tralongo P, Ferraù F, Borsellino N, Verderame F, Caruso M, Giuffrida D, Butera A, Gebbia V

Therapeutics and Clinical Risk Management 2011, 7:387-392

Published Date: 9 September 2011

Multidisciplinary care in pediatric oncology

Cantrell MA, Ruble K

Journal of Multidisciplinary Healthcare 2011, 4:171-181

Published Date: 30 May 2011

Pegylated liposomal doxorubicin in the management of ovarian cancer

Gabriella Ferrandina, Giacomo Corrado, Angelo Licameli, et al

Therapeutics and Clinical Risk Management 2010, 6:463-483

Published Date: 29 September 2010